MYC and triple-negative breast carcinoma: We previously demonstrated, at the preclinical level, the potent effect of Omomyc monotherapy in metastatic breast cancer and particularly in triple-negative breast cancer (TNBC),11 an aggressive subtype where MYC is disproportionally elevated as compared to other breast cancer molecular subtypes.17